FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3084157413> ?p ?o ?g. }

• W3084157413 abstract "Background: Men are at greater risk for cardiovascular disease (CVD) than women until after menopause. For this reason, androgens have been implicated as playing a role in CVD in men. We have studied the role that androgens play in mediating the hypertension (HT) in spontaneously-hypertensive rats (SHRs), and found that blood pressure (BP) is decreased with castration and increased with testosterone supplements. In addition, we found that androgen receptor (AR) antagonists reduce BP, but blockers of the conversion of testosterone to dihydrotestosterone have no effect on BP, suggesting that testosterone alone is capable of mediating HT in male SHR. Testosterone is known to induce genomic and non-genomic effects via binding to nuclear AR or via independent mechanisms caused by membrane-bound AR. It is unclear whether or not membrane-bound AR play a role in mediating HT in male SHRs. In the present study we tested the hypothesis that only nuclear AR, not membrane-bound AR, mediate the HT in male SHR. Methods: Male SHR (aged 13 months; n = 5 - 6 rats/group) were implanted with radiotelemeters, and after 2 weeks recovery, mean arterial pressure (MAP) was measured for 4 days (baseline). Then rats were given vehicle (dimethylacetamide, DMA, 1 ml/kg, s.c.); bicalutamide (BICA, nuclear AR antagonist; 5 mg/k/d, s.c.); or Asc-j9 (AR degradation enhancer, 50 mg/kg/d, s.c.) for 8 days while measuring their MAP. Asc-j9 degrades both nuclear and membrane-bound AR. Results: Both BICA and Asc-j9 reduced MAP in male SHRs (BICA: 171 ± 2 to 151 ± 1 mmHg, p < 0.05; Asc-j9: 172 ± 3 to 148 ± 2 mmHg, p < 0.05.). DMA vehicle also reduced MAP (176 ± 5 to 161 ± 4 mmHg, p < 0.05). The decrease in the BICA and Asc-j9 groups was significantly different than the DMA group. Conclusion: In summary, AR degradation enhancer, that degrades both membrane-bound and nuclear AR, reduced MAP to similar level as nuclear AR antagonist in male SHR, suggesting that it is the nuclear AR that plays a greater role in mediating chronic BP control in male SHR. It is likely that membrane-bound AR may mediate more acute effects of androgen function independent of the BP." @default.
• W3084157413 created "2020-09-14" @default.
• W3084157413 creator A5059791821 @default.
• W3084157413 creator A5085377296 @default.
• W3084157413 date "2020-09-01" @default.
• W3084157413 modified "2023-09-27" @default.
• W3084157413 title "Abstract P209: Androgen Receptor Antagonist, Bicalutamide, And Androgen Receptor Degradation Enhancer, Asc-j9, Decrease Blood Pressure Similarly In Male Spontaneously-hypertensive Rats." @default.
• W3084157413 doi "https://doi.org/10.1161/hyp.76.suppl_1.p209" @default.
• W3084157413 hasPublicationYear "2020" @default.
• W3084157413 type Work @default.
• W3084157413 sameAs 3084157413 @default.
• W3084157413 citedByCount "0" @default.
• W3084157413 crossrefType "journal-article" @default.
• W3084157413 hasAuthorship W3084157413A5059791821 @default.
• W3084157413 hasAuthorship W3084157413A5085377296 @default.
• W3084157413 hasConcept C121608353 @default.
• W3084157413 hasConcept C126322002 @default.
• W3084157413 hasConcept C134018914 @default.
• W3084157413 hasConcept C170493617 @default.
• W3084157413 hasConcept C185592680 @default.
• W3084157413 hasConcept C2776885963 @default.
• W3084157413 hasConcept C2777911890 @default.
• W3084157413 hasConcept C2779279991 @default.
• W3084157413 hasConcept C2779881493 @default.
• W3084157413 hasConcept C2780192828 @default.
• W3084157413 hasConcept C2780962315 @default.
• W3084157413 hasConcept C61367390 @default.
• W3084157413 hasConcept C71315377 @default.
• W3084157413 hasConcept C71924100 @default.
• W3084157413 hasConcept C84393581 @default.
• W3084157413 hasConceptScore W3084157413C121608353 @default.
• W3084157413 hasConceptScore W3084157413C126322002 @default.
• W3084157413 hasConceptScore W3084157413C134018914 @default.
• W3084157413 hasConceptScore W3084157413C170493617 @default.
• W3084157413 hasConceptScore W3084157413C185592680 @default.
• W3084157413 hasConceptScore W3084157413C2776885963 @default.
• W3084157413 hasConceptScore W3084157413C2777911890 @default.
• W3084157413 hasConceptScore W3084157413C2779279991 @default.
• W3084157413 hasConceptScore W3084157413C2779881493 @default.
• W3084157413 hasConceptScore W3084157413C2780192828 @default.
• W3084157413 hasConceptScore W3084157413C2780962315 @default.
• W3084157413 hasConceptScore W3084157413C61367390 @default.
• W3084157413 hasConceptScore W3084157413C71315377 @default.
• W3084157413 hasConceptScore W3084157413C71924100 @default.
• W3084157413 hasConceptScore W3084157413C84393581 @default.
• W3084157413 hasIssue "Suppl_1" @default.
• W3084157413 hasLocation W30841574131 @default.
• W3084157413 hasOpenAccess W3084157413 @default.
• W3084157413 hasPrimaryLocation W30841574131 @default.
• W3084157413 hasRelatedWork W1965833776 @default.
• W3084157413 hasRelatedWork W1979102595 @default.
• W3084157413 hasRelatedWork W1979452793 @default.
• W3084157413 hasRelatedWork W1981433740 @default.
• W3084157413 hasRelatedWork W2000206763 @default.
• W3084157413 hasRelatedWork W2004261902 @default.
• W3084157413 hasRelatedWork W2026882188 @default.
• W3084157413 hasRelatedWork W2040570848 @default.
• W3084157413 hasRelatedWork W2083564258 @default.
• W3084157413 hasRelatedWork W2103250319 @default.
• W3084157413 hasVolume "76" @default.
• W3084157413 isParatext "false" @default.
• W3084157413 isRetracted "false" @default.
• W3084157413 magId "3084157413" @default.
• W3084157413 workType "article" @default.